| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Esperion Therapeutics, Inc. |
| 3621 S. State Street, 695 KMS Place, Ann Arbor, MI 48108 * (734) 332-0506 |
| Business Description | The company discovers and develops pharmaceutical products for the treatment of cardiovascular diseases. |
| Offering Information Company has | |||
| Trading As | ESPR (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 2/24/00 |
| Domestic Shares Offered | 6,000,000 | Offer Date | 8/9/00 |
| Foreign Shares Offered | 0 | Filing Range | $8.00 - $10.00 |
| Company Shares | 6,000,000 | Offer Price | $9.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.630 |
| Gross Proceeds | $54,000,000 | Selling | $0.370 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 24,020,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Robertson, Stephens & Company | Lead Manager | (415) 989-8500 |
| Chase H&Q; | Co-manager | (415) 439-3626 |
| U.S. Bancorp Piper Jaffray | Co-manager | (612) 342-6220 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/98 | 12/31/99 | |||||
| Revenues | - | - | - | 0.000 | 0.000 | - | - |
| Income from Oper. | - | - | - | -2.387 | -11.002 | - | - |
| Net Income | - | - | - | -2.143 | -10.670 | - | - |
| E.P.S | - | - | - | -1.060 | -4.270 | - | - |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -7.86 | - | - | ||||
| Cash Flow - Inv. | -1.56 | - | - | ||||
| Cash Flow - Fin. | 2.78 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 8.00 | Current Assets | 6.04 | Current Ratio | 2.08 |
| Total Liab. | 5.18 | Current Liab. | 2.90 | Debt Ratio | 64.81% |
| Total Equity | 2.81 | Working Cap. | 3.14 | Debt to Equity Ratio | 1.84 |
| Cash | 5.90 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for further development and commercialization of our product candidates, ongoing research and development, payments under licensing agreements and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Morgan, Lewis & Bockius |
| Bank's Law Firm | Testa, Hurwitz & Thibeault |
| Registrar/Transfer Agent | StockTrans, Inc. |
| Auditor | Arthur Andersen |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Oak Investment Partners | 25.14 | |
| TL Ventures III | 23.51 | |
| HealthCap KB | 14.34 | |
| Canaan Equity Partners | 9.28 | |
| Avalon Investments | 4.71 | |
| Novare Kapital | 4.63 | |
| Note: represents ownership of 5% or more prior to the offering. | ||